Obesity costs the NHS £11.4 billion a year. For the whole economy, that figure rises to £74.3 billion.¹ This is the government’s own estimate, cited in the Health and Social Care Committee’s recent report on obesity and the food environment. 

These are costs the NHS is already enduring today, in appointments, admissions and long-term management of chronic conditions and complications linked to obesity. Much of it could have been prevented or better managed with the right pathway in place from the start.

Whilst long-term outcomes data on newer obesity treatments are still maturing, the economics of leaving it undertreated are already well understood. Every patient who does not receive structured, effective obesity care, is a patient whose costs shift elsewhere, into acute services and social care. In addition, this reduces quality of life and productivity which earlier intervention could have avoided.

This is why NHS commissioners and Government need to treat investment in structured obesity care as a funding priority. Specialist personalised obesity services, combining clinical oversight with integrated behavioural and nutritional support, offer an opportunity to intervene before costs escalate, by helping patients sustain treatment and reduce the risk of developing of obesity-related complications.

Working with East Suffolk and North Essex Foundation Trust (ESNEFT), Reset Health has successfully reduced specialist weight management referral waiting times from two years to just eight days. Careful, personalised dosing has cut medication costs by nearly 18 percent, and this has been achieved in a patient cohort with average BMI above 47 with multiple comorbidities. The programme has achieved 96 per cent retention at six months,² against typical real-world attrition of 30 to 40 per cent.³‍

Applied at scale, the medication efficiencies demonstrated in this programme could translate into meaningful savings for the NHS, alongside improved access and retention. This is what effective investment in obesity care returns. Better outcomes for patients, and genuine reinvestment capacity for a system that badly needs it.

The NHS is already spending vast sums on obesity, just much later and less effectively than it needs to. Obesity care, built earlier around the patient instead of precariously bolted on afterwards, is how that spend starts working for the system instead of against it.

¹ Health and Social Care Committee, 2026. ‘Stand up to food industry’ after decades of failure to tackle obesity epidemic, MPs tell government. UK Parliament, 15 July 2026. Available at: Resource

² Curtis T, et al., 2026. Comparative economic analysis of response-guided titration of incretin therapies versus standard models: A 6-month real-world evaluation in an integrated, digital obesity clinic. Obesity Facts, 19(Suppl. 1), Abstract AD08.04. doi:10.1159/000551826. Available at: Resource

³ Curtis T, et al., 2026. High adherence to incretin-based therapy for obesity despite adverse events: Six-month results from the Roczen high engagement digital service in state-funded (NHS) patients. Obesity Facts, 19(Suppl. 1), Abstract TS04.03. doi:10.1159/000551826. Available at: Resource

‍